Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
300 participants
INTERVENTIONAL
2001-08-31
2003-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Seloken ZOK/Toprol-XL
50 mg
Seloken ZOK/Toprol-XL
200 mg
Placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented ejection fraction less than 0.40.
* Must be able to comply with all study procedures.
Exclusion Criteria
* Have heart problems that would not allow B-blocker therapy.
* Receiving B-blockers therapy for any medical reason including topical B-blockers that might cause systemic absorption (e.g., glaucoma).
* Undergone certain heart surgeries, such as, prior heart transplant or cardiomyoplasty.
* Have certain heart diseases.
* Pregnant or breast feeding.
* Unlikely to survive.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Mobile, Alabama, United States
Little Rock, Arkansas, United States
Los Angeles, California, United States
Northridge, California, United States
Redondo Beach, California, United States
Riverside, California, United States
Research Site
Farmington, Connecticut, United States
Clearwater, Florida, United States
Melbourne, Florida, United States
Vero Beach, Florida, United States
Augusta, Georgia, United States
Indianapolis, Indiana, United States
Jeffersonville, Indiana, United States
Edgewood, Kentucky, United States
New Orleans, Louisiana, United States
Shreveport, Louisiana, United States
Auburn, Maine, United States
Baltimore, Maryland, United States
Salisbury, Maryland, United States
Boston, Massachusetts, United States
Saint Charles, Missouri, United States
St Louis, Missouri, United States
Omaha, Nebraska, United States
Albuquerque, New Mexico, United States
Buffalo, New York, United States
East Syracuse, New York, United States
New York, New York, United States
Rochester, New York, United States
The Bronx, New York, United States
Williamsville, New York, United States
Burlington, North Carolina, United States
Columbus, Ohio, United States
Oklahoma City, Oklahoma, United States
Flourtown, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Lincoln, Rhode Island, United States
Wakefield, Rhode Island, United States
Tyler, Texas, United States
Salt Lake City, Utah, United States
Chesapeake, Virginia, United States
Roanoke, Virginia, United States
Green Bay, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Colucci WS, Kolias TJ, Adams KF, Armstrong WF, Ghali JK, Gottlieb SS, Greenberg B, Klibaner MI, Kukin ML, Sugg JE; REVERT Study Group. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation. 2007 Jul 3;116(1):49-56. doi: 10.1161/CIRCULATIONAHA.106.666016. Epub 2007 Jun 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
USMET0002
Identifier Type: -
Identifier Source: secondary_id
276
Identifier Type: -
Identifier Source: org_study_id